An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months.

Trial Profile

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2013

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2012 Actual patient number changed from 479 to 514 as reported by ClinicalTrials.gov.
    • 04 Oct 2011 Detailed results are expected to be presented at the 54th Annual Scientific Meeting of the American Headache Society (AHS), as reported in a NuPathe media release.
    • 03 Oct 2011 Status changed from active, no longer recruiting to completed, according to a NuPathe media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top